We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App





Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond

By LabMedica International staff writers
Posted on 07 Aug 2019
Print article
Image: The cobas 8100 automated workflow series (Photo courtesy of Roche).
Image: The cobas 8100 automated workflow series (Photo courtesy of Roche).
Roche Diagnostics (Basel, Switzerland) launched its presence at the American Association for Clinical Chemistry (AACC) 2019 Clinical Lab Expo by showcasing how health networks are driving change in the lab and beyond. Roche showcased the latest solutions from its clinical lab portfolio, including chemistry, molecular and point-of-care diagnostics, automation and digital diagnostics. The company also provided a glimpse into its diagnostics products that are not yet available for sale in the U.S.

Roche continues to expand the Integrated Core Lab by consolidating and integrating a wider range of platforms across other disciplines that include molecular diagnostics and testing in coagulation, hematology and urinalysis. Roche solutions are also designed to address the lab's future needs, with pre-analytics and the next generation of automation that provides the ability to expand into liquid-based cytology and compatible analytics, all potentially connectable. The automation area included a fully automated configuration of an integrated core lab that consolidates routine chemistry and molecular testing.

Among the products highlighted by Roche at AACC 2019 was its cobas pro integrated solutions — an integrated mid-to-high volume solution for clinical chemistry and immunochemistry testing needs that is designed to achieve reduced maintenance and increased throughput through a scalable and modular system. The company showcased cobas prime — a pre-analytical system designed for standard processing and cross-contamination control of molecular samples — and cobas e 801 module — a high-volume immunoassay platform that provides nearly twice the throughput on the same footprint as its predecessor.

Roche also showcased cobas c 513 — a fully automated chemistry analyzer that raises the standard in HbA1c testing throughput — and the cobas 6800 system — a fully-automated, moderate-complexity platform that brings transformational efficiency gains to molecular diagnostics. The company also highlighted the cobas Connection Module (CCM) — a high-volume automation solution that provides connectivity across disciplines and third-party platforms — and the cobas Liat PCR system — a point-of-care analyzer with CLIA-waived, real-time PCR tests for flu A/B, flu A/B + RSV and strep A that provide lab-quality results in 20 minutes or less.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.